Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ziresovir (AK0529) in Healthy Subjects
NCT02297594Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Ziresovir with Placebo (2 arms). Primary endpoint: Number of participants with adverse events, serious adverse events. Started Oct 2014; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02297594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297594.